BOSTON, Mass. — PureTech Health plc announced that its Board of Directors has appointed Robert Lyne as Chief Executive Officer and a member of the board, effective immediately.
Lyne succeeds the interim role he has held since July 2025. He joined PureTech in January 2024 as chief portfolio officer and has overseen progress across the company’s programs while advancing strategic and operational priorities.
“I’m honored to lead PureTech as CEO at such an important moment in its evolution,” Lyne said. “Over the past two years, I’ve seen first-hand the strength of our programs, the talent of our team, and the power of our differentiated model. I’m keen to build on this foundation, working closely with the Board to drive the next phase of execution as we advance transformative therapies for patients and deliver long-term value for our shareholders.
“Our immediate focus is on securing the funding needed to advance our newest Founded Entity, Celea Therapeutics, following the successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration. This process is progressing, and we expect to close within the first half of 2026, after which PureTech’s operational run rate will reduce significantly. In parallel, we are also actively pursuing financing in 2026 for Gallop Oncology, as the strong initial topline data continue to mature, and the program advances to the next stage of development.
“Going forward, we intend to operate with a streamlined structure and significantly reduced overhead. This will be combined with a disciplined investment posture, pursuing focused innovation initiatives that can be advanced to key inflection points with relatively modest spend to improve our return on capital. Once Celea is fully financed, we expect to evaluate the most effective means of delivering value to shareholders, including potential capital returns, as part of an integrated strategy that continues targeted and impactful innovation. In the meantime, our priority is preserving capital, maintaining flexibility, and positioning PureTech for value creation.”
Sharon Barber-Lui, interim chair of PureTech’s board of directors, said Lyne’s appointment reflects confidence in his leadership and strategic direction.
“We are pleased to appoint Rob as PureTech’s CEO,” Barber-Lui said. “As Interim CEO, Rob has demonstrated strong leadership, strategic clarity, and a deep understanding of the business and key stakeholders. Rob’s appointment positions the Company to execute against a clear plan to sharpen strategic and operational focus and optimize shareholder returns. The Board supports Rob’s disciplined approach to maintaining a lean operating model whilst concentrating on capital-efficient innovation to maximize shareholder value. The Board is confident that Rob is the right person to lead PureTech forward.”
Lyne previously served as CEO of Arix Bioscience plc and brings more than a decade of experience in senior leadership roles at London-listed life science companies. His background includes governance, executive leadership, and participation in more than 80 venture capital financings across Europe and North America, as well as multiple portfolio exits and initial public offerings.
PureTech is a hub-and-spoke biotherapeutics company focused on advancing innovative medicines and translating scientific discovery into long-term value.
